Clinical Trials
8 trialsNCT03643549 2024-02-29
BORTEM-17
Haukeland University Hospital
Phase 1/2 Unknown
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT00184015 2017-04-11
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
University of Southern California
Phase 1/2 Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT02145715 2015-06-26
MUKsix
University of Leeds
Phase 1/2 Unknown
NCT00334932 2014-01-10
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00431990 2011-08-12
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT00516100 2010-01-15
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Aptium Oncology Research Network
Phase 1/2 Unknown